Literature DB >> 3595648

Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol.

W M van Aalderen, H Knoester, K Knol.   

Abstract

A 10-year-old girl with cervical tuberculosis was treated with Isoniazid, Rimfampicin and Ethambutol. After 2 weeks of treatment a hepatotoxic reaction developed. Withdrawal of therapy resulted in complete clinical improvement and in normalization of all laboratory measurements. Treatment was restarted with Rifampicin, Pyrazinamid and Ethambutol. Liver enzyme levels were monitored weekly. Seven weeks after this three-drug regiment was started, all therapy was discontinued because of elevated liver enzyme levels. However, the patient died 2 weeks later of progressive fulminant hepatitis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595648     DOI: 10.1007/bf00716476

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  6 in total

1.  Hepatotoxicity of rifampicin and isoniazid in children.

Authors:  M Casteels-Van Daele; L Igodt-Ameye; L Corbeel; R Eeckels
Journal:  J Pediatr       Date:  1975-05       Impact factor: 4.406

2.  [Jaundice and rifampicin. Critical study].

Authors:  T Nebout; D Dhumeaux; P Berthelot
Journal:  Nouv Presse Med       Date:  1974-03-23

3.  Hepatotoxicity in rifampin-isoniazid treated patients related to their rate of isoniazid inactivation.

Authors:  J Smith; W F Tyrell; A Gow; G W Allan; A W Lees
Journal:  Chest       Date:  1972-06       Impact factor: 9.410

4.  [Jaundice during treatment with rifampicin (12 cases)].

Authors:  R Lesobre; J Ruffino; L Teyssier; F Achard; G Brefort
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1969 Apr-May

5.  Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients.

Authors:  R B Byrd; B R Horn; D A Solomon; G A Griggs
Journal:  JAMA       Date:  1979-03-23       Impact factor: 56.272

6.  Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.

Authors:  C Grönhagen-Riska; P E Hellstrom; B Fröseth
Journal:  Am Rev Respir Dis       Date:  1978-09
  6 in total
  2 in total

Review 1.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  Antituberculosis drug-induced hepatotoxicity in children.

Authors:  Peter R Donald
Journal:  Pediatr Rep       Date:  2011-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.